Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2026-01-26 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
Regulatory Filings Classification · 95% confidence The document is a press release issued by BioArctic AB regarding a regulatory update (Priority Review granted by the FDA for a supplemental Biologics License Application). It details clinical trial results and regulatory progress for the drug Leqembi. As it is a general regulatory announcement regarding company operations and product development that does not fit into specific financial reporting categories like 10-K or Earnings Release, it is classified as a Regulatory Filing (RNS).
2026-01-26 English
Tilläggsansökan om marknadsgodkännande av Leqembi® Iqlik™ (lecanemab-irmb) som subkutan startbehandling tilldelas prioriterad granskning av FDA i USA
Regulatory Filings Classification · 95% confidence The document is a press release from BioArctic AB announcing that their partner, Eisai, has been granted priority review by the FDA for a supplemental application (sBLA) regarding the Leqembi Iqlik subcutaneous autoinjector. It details the regulatory status, clinical context, and implications of this development. As it is a standard corporate announcement regarding regulatory progress and product development, it falls under the 'Regulatory Filings' category, which serves as the catch-all for general regulatory announcements that do not fit into more specific categories like M&A or financial results.
2026-01-26 Swedish
Ansökan om marknadsgodkännande för subkutan behandling med Leqembi® inlämnad och accepterad i Kina
Regulatory Filings Classification · 95% confidence The document is a press release from BioArctic AB announcing that their partner, Eisai, has submitted and received acceptance for a marketing authorization application for a subcutaneous treatment of Leqembi in China. This is a standard corporate regulatory announcement regarding product development and regulatory progress. Since it does not fit into specific categories like 'Earnings Release' (it is not a financial results announcement) or 'M&A', it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-01-06 Swedish
BLA for subcutaneous formulation of Leqembi® accepted in China
Regulatory Filings Classification · 95% confidence The document is a press release issued by BioArctic AB regarding the acceptance of a Biologics License Application (BLA) for a subcutaneous formulation of Leqembi in China. It provides details on the regulatory status, clinical implications, and the partnership with Eisai. As it is a general corporate announcement regarding regulatory progress and does not fit into specific financial reporting categories like 10-K, ER, or IR, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-01-06 English
Number of shares and votes in BioArctic AB (publ) as of November 28, 2025
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a change in the total number of shares and votes in BioArctic AB due to the exercise of stock options. This type of disclosure, which details changes in share capital and voting rights, is classified under 'Share Issue/Capital Change' (SHA) as it directly relates to the issuance of new shares and the resulting update to the company's capital structure.
2025-11-28 English
Antal aktier och röster i BioArctic AB (publ) per den 28 november 2025
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a change in the total number of shares and votes in BioArctic AB due to the exercise of warrants from a personnel option program. This type of disclosure regarding changes in share capital and voting rights is a standard regulatory requirement for listed companies, which falls under the category of share issues or capital changes.
2025-11-28 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.